FDC Ltd
Stock Snapshot
Price Performance
Vista Outlook
Basis of our Recommendation
FDC Limited is currently navigating a transformative phase, with management emphasizing a strategic pivot towards high-value therapeutic areas such as GLP-1 agonists and biosimilars. This focus is expected to bolster revenue growth, supported by a robust product pipeline and successful USFDA approvals. However, challenges remain, particularly from regulatory complexities and supply chain issues in the UK, which could impact short-term performance. Vista's financial outlook reflects stable revenue growth and margins, aligning with management's commitment to operational efficiency and R&D-led innovation. The favorable currency depreciation is anticipated to enhance export revenues, while the competitive landscape remains fragmented, posing both opportunities and risks. Over the next 12-24 months, FDC's ability to execute its strategic initiatives will be critical, with key opportunities in expanding its product offerings and enhancing digital capabilities. Conversely, rising input costs and pricing pressures in the US market present significant headwinds that could temper profitability. Overall, while the long-term growth potential remains intact, cautious investor sentiment and mixed macroeconomic signals suggest a careful approach to investment in FDC
Why We Like This Stock
- Management's strategic pivot towards high-value therapeutic areas is expected to drive revenue growth
- Successful USFDA approvals and expansion into emerging markets enhance FDC's competitive position
- Favorable currency depreciation is likely to uplift export revenues
Things To Watch Out For
- Regulatory complexities and supply chain issues in the UK may hinder near-term performance
- Rising input costs could pressure profit margins across various segments
- Pricing pressures in the US market may impact revenue generation
Key Parameters
Financial Snapshot
View Technicals Analysis →| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 1,943 | 2,108 | 2,171 | 2,192 | 2,381 |
| Profit Before Tax (Cr.) | 375 | 347 | 396 | 349 | 393 |
| PBT Margin | 19.3% | 16.5% | 18.2% | 15.9% | 16.5% |
| Net Profit (Cr.) | 292 | 264 | 304 | 268 | 302 |
| Earnings Per Share | 17.9 | 16.2 | 18.7 | 16.5 | 18.5 |
Analyst Recommendations
No analyst recommendations available.
Company Overview
Show Company Profile
FDC Limited, together with its subsidiaries, manufactures and trades in pharmaceutical products in India, the United States, and internationally. The company offers pharmaceutical formulations for various therapeutic segments, including anti-infectives, gastroenterology, ophthalmology, anti-diabetics, cardiovascular care, respiratory care, gynaecology, dermatology, paediatrics, analgesics, vitamins, and nutritional health in the form of tablets, capsules, oral liquids, ophthalmic drops, topical preparations, and paediatric-friendly solutions. It also provides functional food, such as flavoured oral rehydration solution powders, ready-to-drink electrolyte beverages, vitamin-enriched supplements, antioxidant blends and protein-fortified drinks; and various active pharmaceutical ingredients. The company sells its products under the Zifi, Zifi-0, Zocon, Mycoderm, Zathrin, Victofol, Cotaryl, Ziglim-M, Amodep-AT, MumMum 1, Victofol Injection, Simyl MCT, Victofol C, Electral, and Enerzal brands. It also exports its products to approximately 50 countries. FDC Limited was founded in 1936 and is based in Mumbai, India.